期刊文献+

水飞蓟宾纳米混悬剂的制备及大鼠体内药动学研究 被引量:5

Studies on Preparation of Silybin Nanosuspension & Its Pharmacokinetics in Rats
下载PDF
导出
摘要 目的:探讨静脉注射用水飞蓟宾纳米混悬剂的制备,并评价其大鼠静注给药后的药动学。方法:通过对水飞蓟宾纳米混悬剂理化性质及稳定性的评价,考察水飞蓟宾纳米混悬剂的制备方法、处方工艺,并以溶液剂为参照考察其在大鼠体内的药动学行为。结果:水飞蓟宾纳米混悬剂的平均粒径是(268.90±9.20)nm,多分散性为0.22±0.12。水飞蓟宾溶液剂及纳米混悬剂的药时曲线下面积分别为(34.92±0.98)μg·h·mL-1和(57.12±3.20)μg·h·mL-1,消除半衰期(t1/2)分别为(3.05±0.06)h和(6.14±0.42)h。结论:制备的水飞蓟宾纳米混悬剂理化性质比较稳定,与溶?液剂相比,延长了药物在体内的驻留时间,具有一定的缓释效果。 Objective: To prepare stable silybin nanosuspension for intravenous injection and to study the drug pharmacokinetic behavior in rats. Methods: By a modified solvent diffusion method with high speed dispersion process, silybin nanosuspensions were prepared and then freeze-dried. The characteristics of the silybin nanosuspension were evaluated and the pharmacokinetic behavior of the silybin nanosuspeusion was also investigated compared with the solution following the intravenous injection to rats. Results: The obtained silybin nanosuspension had a size of (268.90 ± 9.20) nm with polydispersity index of 0.22 ± 0.12. The silybin in the uanosuspension became amorphous. Pharmacokinetic behavior of the silybin nanosuspension in rots was investigated compared with the solution. The AUC was increased from (34.92 ± 0.98)μg· h· mL^-1 to (57.12 ± 3.20)μg· h· mL^-1 and the biological half-life(t1/2β) extended from(3.05 ± 0.06) h to (6.14 ± 0.42) h. Conclusion: In Comparison with the SLB-S, the SLB-NS prolongs the residence time in vivo, which shows some slow-release effect.
出处 《抗感染药学》 2009年第3期153-157,共5页 Anti-infection Pharmacy
关键词 水飞蓟宾 纳米混悬剂 自微乳化 高速分散 药动学 silybin nanosuspension solvent diffusionmethod high speed dispersion pharmacokinetic behavior
  • 相关文献

参考文献9

  • 1Jiraporn CK.Nanosuspeasion Technology for Drug Delivery[J].Walailak J Sci & Tech,2007,4(2):139-153.
  • 2SunTM LiX.Advances in the research of pharmacology of silymarm.中草药,2000,31(3):229-231.
  • 3Wellington K.Jarvis B.Silymarin:a review of its clinical properties in the management ofhepatic disorders[J].Bio Drugs,2001,15(7):465-489.
  • 4Peters K.Preparation of a clofazimine nanosaspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infevion[J].J Antimcrob Chem,2000,45:77-83.
  • 5Qumtanar-Guerrero D,Tamayo-Esquivel,D.,Ganem-Quintanar,A.,Alluemann E.Doelker E.Adaptation and optimization of the emulsiucation-diffusion technique to prepare lipidic nanospheres[J].Eur J Pharm.2005,26:211-218.
  • 6Muller RH,Bohm BH,Grau MJ.Nanosuspensions:a formulation approach for poorly soluble and poorly bioavailable drugs//In:Wise DL.Handbook of Pharmaceutical Controlled Release Technology:1 st[M].Marcel Dekker,New York,2000:345-357.
  • 7Jacobs C,Kayser O,Mullet RH.Nanosaxspernsions as a new approach for the formulation for the poorly soluble drug tarazepide[J].Inter J Pharm,2000,196:161-164.
  • 8SHE Zuo-Yan,KE Xue.Preparation of breviscapine nanosuspension and its pharmacokinetic behavior in rats[J].Chin J Nat Med Jan,2007,15(11):50-55.
  • 9Muller RH,Peters K.Nanosuspensions for the formulation of poorly soluble chugs I.Preparation by sine-reduction technique[J].Int J Pharm,1998,160:229-237.

同被引文献64

引证文献5

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部